[ad_1]
“It is a crucial time to join Truveta and be part of the solution to leverage our clinical data to advance care for our patients and for patients around the world,” Dr. Melinda Estes, president and CEO of Saint Luke’s Health System, said in a news release. Large-scale data analysis can lead to insights that inform public health and healthcare delivery, she said.
Truveta also unveiled a data platform, built on Microsoft’s Azure cloud, that allows researchers and life sciences companies to analyze aggregated and de-identified patient data from the company’s health system members. Truveta uses artificial intelligence to de-identify and structure data so that it can be uploaded from health systems to Truveta daily.
The company declined to disclose how much it will charge researchers to access its data. Participating health systems can tap utilize the tool as part of their memberships.
Truveta will license the data platform for “ethical medical research” and the information will not be used to target advertising toward patients or physicians, according to the company. Researchers and life science companies can use these data to monitor the safety and effectiveness of drugs and medical devices and to explore new uses for those products, according to Truveta.
In an initial study conducted on the platform, Truveta researchers analyzed patient data to assess adverse events and breakthrough infection rates associated with the Pfizer-BioNTech, Moderna and Johnson & Johnson COVID-19 vaccines. The project took less than two weeks to complete, according to Truveta.
Less than 1% of fully vaccinated patients experienced adverse events, according to Truveta’s findings. There were roughly 18,000 breakthrough cases out of 1.7 million fully vaccinated patients included in the Truveta data. Of fully vaccinated patients who became infected, between 9% and 15% were hospitalized.
[ad_2]
Source link
